Page last updated: 2024-12-11
hemiasterlin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hemiasterlin A: potent cytotoxic peptide from marine sponge, Hemiasterella minor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5352091 |
CHEMBL ID | 457755 |
SCHEMBL ID | 6671779 |
MeSH ID | M0270501 |
Synonyms (6)
Synonym |
---|
NSC695241 , |
hemiasterlin a |
CHEMBL457755 |
hemiasterlins a |
(e,4s)-4-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-3-methyl-2-(methylamino)butanoyl]amino]-3,3-dimethylbutanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid |
SCHEMBL6671779 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID354405 | Antimitotic activity against human MCF7 cells expressing p53 mutant by MTT assay | 2003 | Journal of natural products, Feb, Volume: 66, Issue:2 | Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. |
AID354406 | Cytotoxicity activity against human MCF7 cells expressing p53 mutant by MTT assay | 2003 | Journal of natural products, Feb, Volume: 66, Issue:2 | Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |